Half Yearly Report and Accounts

• Loss from ordinary activities after tax increased by 51.9% to $1,297,938
• No dividends paid, recommended, or declared during the period
• Successfully completed Phase 1 trial for IRX-616a with no Serious Adverse Events
• Temporarily suspended IRX-211 and IRX-616a clinical studies due to funding issues
• Seeking alternate funding to continue clinical trial programs

Nexalis Therapeutics Ltd reported a loss from ordinary activities after tax of $1,297,938 for the half-year ended June 30, 2026, an increase of 51.9% from the previous period. The company did not pay, recommend, or declare any dividends. The company successfully completed Phase 1 of the IRX-616a trial, with no Serious Adverse Events reported. However, the remaining study activities for IRX-211 and IRX-616a were temporarily suspended due to funding issues from the cancellation of the LFO Facility. Nexalis is now seeking alternate funding to continue its clinical trial programs.

Nexalis Therapeutics Ltd expects to continue seeking alternate funding to resume clinical trial programs.

Nexalis Therapeutics Ltd is actively seeking alternate funding to resume its clinical trial programs and progress its drug development initiatives.